VedaBio
Frederic D. Sweeney has held various senior roles in the field of life sciences and diagnostics. Currently serving as the Director, President, and CEO at VedaBio, Frederic D. leads a team of industry experts in pushing the boundaries of molecular detection. Previously, Frederic D. also held positions at OMX Ventures, Qvella Corporation, CTRL Therapeutics, MeMed, Northern Biologics, Banyan Biomarkers Inc, bioMerieux, and T2 Biosystems, showcasing their extensive experience in strategic development, corporate leadership, and venture capital investments. With a strong academic background, including a PhD in Molecular and Medical Genetics, Frederic D. Sweeney continues to make significant contributions to the advancement of healthcare and diagnostics.
This person is not in any teams
VedaBio
Veda is derived from the Sanskrit word for the creation of knowledge. With our team of industry leading experts, we operate at the forefront of scientific innovation to push the limits of what’s possible in the field of molecular detection. VedaBio is unlocking a universe of possibilities in molecular biology with a breakthrough platform for near-instant molecular detection of highly multiplexed analytes, delivering best-in-class accuracy without the need for target amplification.